Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Proof of Principle Program - Phase I

McGill University

$160,000.00

Novel first-in-class MT2 melatonin receptor partial agonists for neuropathic pain

FY 2015-16

Summary
Neuropathic pain (NP) is a chronic pain disorder characterized by severe pain that develops following nerve damage, resulting from conditions such as shingles, traumas, injury, amputation, autoimmune inflammation and cancer. It is a permanent pain that persists for months or years, afflicting a significant number of patients, resulting in personal suffering, reduced productivity, and substantial health care costs. The Canadian government spends an estimated $6 billion/year for the treatment of chronic pain, while approximately 56% of Canadians have experienced moderate-to-severe pain in the past 3 months. Two-third of patients with diverse chronic pain conditions complain of significant sleep disturbance. Therapeutics for chronic pain is scant and available drugs have many side effects. Melatonin, a neurohormone produced by the pineal gland, and binding two receptors, called MT1 and MT2 could be implicated in pain physiology. In particular, my laboratory discovered that the MT2 receptor subtype might be a novel target for neuropathic pain. We discovered that a novel selective MT2 melatonin drug, called UCM924, at low doses, possesses potent analgesic properties pain in preclinical tests. In the present proposal, we intend to strengthen this invention position and move UCM924 toward clinical phases and commercialization, hoping that this novel drug will be available for Canadian patients suffering from chronic pain.
Program
Proof of Principle Program - Phase I
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
335043
Name
Gobbi Gabriella
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Novel first-in-class MT2 melatonin receptor partial agonists for neuropathic pain
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$160,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Analgesic; Drug Discovery; Gpcr; Lead Optimization; Melatonin; Mt2 Receptor; Neuropathic Pain; Pain
Abstract
Neuropathic pain (NP) is a chronic pain disorder characterized by severe pain that develops following nerve damage, resulting from conditions such as shingles, traumas, injury, amputation, autoimmune inflammation and cancer. It is a permanent pain that persists for months or years, afflicting a significant number of patients, resulting in personal suffering, reduced productivity, and substantial health care costs. The Canadian government spends an estimated $6 billion/year for the treatment of chronic pain, while approximately 56% of Canadians have experienced moderate-to-severe pain in the past 3 months. Two-third of patients with diverse chronic pain conditions complain of significant sleep disturbance. Therapeutics for chronic pain is scant and available drugs have many side effects. Melatonin, a neurohormone produced by the pineal gland, and binding two receptors, called MT1 and MT2 could be implicated in pain physiology. In particular, my laboratory discovered that the MT2 receptor subtype might be a novel target for neuropathic pain. We discovered that a novel selective MT2 melatonin drug, called UCM924, at low doses, possesses potent analgesic properties pain in preclinical tests. In the present proposal, we intend to strengthen this invention position and move UCM924 toward clinical phases and commercialization, hoping that this novel drug will be available for Canadian patients suffering from chronic pain.
Competitiondate
201509
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gobbi, Gabriella
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $160,000~ $0~